Author:
Eisenhauer Anton,Sönnichsen Sönke,Hastuti Agustina,Shroff Rukshana,Heuser Alexander,Kolevica Ana,Lubnow Amarin,Brandt Burkard,Müller Michael
Funder
GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel
Helmholtz Association
Reference31 articles.
1. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women;Bone;J. Clin. Endocrinol. Metab.,2008
2. Denosumab for prevention of fractures in postmenopausal women with osteoporosis;Cummings;N. Engl. J. Med.,2009
3. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension;Papapoulos;J. Bone Miner. Res.,2012
4. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study;Fizazi;Lancet,2011
5. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial;Coleman;Lancet Oncol.,2020